Year: 2021

Third dose trial, Cov-Boost study https://www.bbc.co.uk/news/health-571… Need for third dose autumn or winter? Factors Variants and vaccine efficacy Longevity of protection Trial starts in June N = 3,000 All ages who had their first dose in December or January Prof Saul Faust, chief investigator, University of Southampton It could be that some age groups may not need a booster and others do The aim is to find out whether there should be a booster campaign and which vaccine to use Vaccines t

ONS antibody survey, May 18th https://www.ons.gov.uk/peoplepopulati… 19th April 69.3% in England 63.2% in Wales 63.5% in Northern Ireland 59.2% in Scotland Highest in the older age groups across the UK Similar across English regions, 64.8% in the South West to 69.7% in the North West. Infection or vaccination? Vaccinations now https://coronavirus.data.gov.uk/detai… First dose 69.9 % Second dose 39.0 % Positive tests Down 2.6% in past 7 days Next stage of roadmap https://www.theguar

UK first vaccine, 8th December US first vaccine, 14th December Czech Republic First vaccine, 15th January Theraputic approved, 8th March India Deaths pass 200,000 https://www.nytimes.com/2021/04/28/wo…​ B.1.617, Maharashtra B.1.1.7, New Delhi https://bookme.airindia.in/AirIndiaB2…​ Immune escape, looking good in India https://www.icmr.gov.in​ Data up to April 21 Extremely low breakthrough infection rate India data, 0.02% to 0.04% of vaccinated people falling ill United States rates, 0.008

The Global Elites want to keep vaccine patents locked. The US remains non-committal on waivers. Now, Bill Gates has said no to lifting patents to share vaccine formulas with the developing world. WION’s Palki tells you how patents on vaccines are the biggest roadblock towards recovery.

Do we need to change vaccination protocols? Department of Pathology and Molecular Medicine, Queen’s University, Kingston, ON, Canada https://ashpublications.org/blood/art…​ Thrombocytopenia has been consistently reported following the administration of adenoviral gene transfer vectors Adenovirus-induced thrombocytopenia is a potentially serious complication of gene therapy protocols using this type of vector. Understanding its mechanism may help the development of measures to prevent this adverse ev

Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine https://www.cdc.gov/media/releases/20…​ https://www.washingtonpost.com/health…​ Cerebral venous sinus thrombosis, together with low platelets Some sort of immune response 6 cases from 6.8 million doses Look out for, severe headache, abdominal pain, leg pain or shortness of breath within three weeks of vaccination Paul A.Offit, vaccine specialist, Children’s Hospital of Philadelphia I think it’s the prudent thing to do I think it